Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells.
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseDeveloping therapeutic approaches to tau, selected kinases, and related neuronal protein targetsDrug Development in Conformational Diseases: A Novel Family of Chemical Chaperones that Bind and Stabilise Several Polymorphic Amyloid StructuresIdentification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for TauopathiesPreventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathiesTau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease modelsDevelopment of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathiesStructure and mechanism of action of tau aggregation inhibitors.In vitro aggregation assays using hyperphosphorylated tau protein.Understanding the kinetic roles of the inducer heparin and of rod-like protofibrils during amyloid fibril formation by Tau proteinGeneralizing the Concept of Specific Compound Formulation Additives towards Non-Fluorescent Drugs: A Solubilization Study on Potential Anti-Alzheimer-Active Small-Molecule Compounds.TOC1: characterization of a selective oligomeric tau antibody.Tau as a therapeutic target in neurodegenerative disease.Modulation and detection of tau aggregation with small-molecule ligandsTau-based treatment strategies in neurodegenerative diseasesInhibition of tau polymerization with a cyanine dye in two distinct model systemsIdentification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening.Azaphilones inhibit tau aggregation and dissolve tau aggregates in vitroAdvances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.The role of tau in Alzheimer's disease and related disorders.Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.Tau as a therapeutic target for Alzheimer's diseaseImmunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology.Potential synergy between tau aggregation inhibitors and tau chaperone modulators.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau.The Potential of Indole/Indolylquinoline Compounds in Tau Misfolding Reduction by Enhancement of HSPB1.Combining in vitro and in silico approaches to find new drugs targeting the pathological proteins related to the Alzheimer's disease.New insights on the interaction mechanism between tau protein and oleocanthal, an extra-virgin olive-oil bioactive componentNMR studies on carbohydrate interactions with DC-SIGN towards a quantitative STD analysis
P2860
Q26739412-E0191C3B-53C5-4088-9D15-DFA9DA42F987Q26865654-EC364E80-F35B-4351-9ECF-BB56B8768B27Q28547692-675323C7-F531-4B0C-AEDA-873670D28616Q28597211-A606C7E2-BA8C-45E2-80A0-259ED1BC2158Q30649677-408B64E0-80DB-4B4C-9C91-1EE10E1D6B32Q30669674-6C18B264-D594-4F5A-A1C9-B42C4A325B7AQ33828966-5D6EE58F-9784-47FC-AA8E-EEDB7F4D3BC5Q33861802-92C0E884-DC9F-418F-B08E-3DFF8BC5E9CDQ34068459-DD7D2B6D-6182-4A1F-80FB-7228EC15ADD4Q34154643-4D33428A-EDC4-4060-8F66-62F1166273CAQ34902096-88F225C3-07E3-4D8F-8A69-BFE2C212B8C0Q35161820-58D7CE83-E057-41AB-90A7-856415667F1CQ35604223-3E449042-467C-4DCC-8762-2A5D484D44A4Q36047276-C2934668-32FC-4A21-B840-8CA7E0F84BD8Q36687306-EF26FCE6-3B86-4CB6-8E51-1F45281D8183Q36970350-68E22292-4632-4474-BF80-12D9DA6089BFQ37050216-4F8D91F6-4D7C-4257-B91B-5711CC91B0D2Q37215861-D9AD01A0-2CAA-4C38-9D53-E0D332B72B7CQ37344041-3FADCE1F-8907-4F8B-9C68-208805430D29Q37412951-4D958A10-21A2-49E4-9EFA-858EB3F0A0A9Q37419558-B8DB308B-BA5B-46C4-B2AE-08D6EA52190EQ37606284-D4F059D0-6A31-4741-9FBE-F507EFD7D960Q37765632-713733CF-26F8-4B23-B8F6-C8AD71CD802AQ37841631-9E7C1AED-5F6F-4347-8680-F940614EDBEBQ37890451-65E25E5E-17E4-4DB3-AAC0-D03ACC99072EQ37984574-57E1F7E2-6B25-4F79-AA32-2548FF2A1659Q38091721-150BDD83-313D-4554-BF2B-5CFEA51436C1Q38138165-E2DF2A71-00FA-449E-9F86-170354C53915Q38715233-9937B8EA-A0CF-498B-899B-FF301A5EDBB5Q38901388-D94C599C-4C3B-4D5A-8A13-7849FD2BD54DQ39035486-55DFCC71-1CE2-4321-9C76-1E18763624CCQ41945501-1D014F21-121E-41DA-9805-5915B3AD8B9EQ42280027-70A8547E-4DCB-469A-9473-C5D050305B05Q46515336-BDE1EA1A-F861-4271-9D8D-6879C2A52FE4Q47396500-65F1F2B0-B115-490C-BB2A-F24C17466217Q56774474-018642D0-94AE-450C-B7B2-F025F4EEB878Q58328189-80D40CCA-6D2C-4457-A4FE-FFF2DB01867E
P2860
Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Phenylthiazolyl-hydrazide and ...... oxicity in vitro and in cells.
@en
type
label
Phenylthiazolyl-hydrazide and ...... oxicity in vitro and in cells.
@en
prefLabel
Phenylthiazolyl-hydrazide and ...... oxicity in vitro and in cells.
@en
P2093
P50
P356
P1433
P1476
Phenylthiazolyl-hydrazide and ...... oxicity in vitro and in cells.
@en
P2093
Atilla Coksezen
Bernd Meyer
Gregor Larbig
Inna Khlistunova
Marcus Pickhardt
P304
10016-10023
P356
10.1021/BI700878G
P407
P577
2007-08-08T00:00:00Z